In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SB Execs: More Pie, Please

Executive Summary

SmithKline's middle managers aren't particularly happy with their financial stake in the new Glaxo SmithKline. Thanks to a new patent on clavulanic acid, SB's #2 drug which was supposed to lose patent protection in 2002, and the withdrawal of a key competitor to SB's new diabetes drug rosiglitazone, SB will probably be providing most of the near-term earnings growth to the combined company. But SB shareholders only get 41% of the combined company. SB employees will therefore be sharing the earnings of their company, reflected in the value of their options, disproportionately with Glaxo employees.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts